Good morning, everyone, and welcome to a new year. We hope the extended respite — for those of you who were able to enjoy — was refreshing and relaxing, because the inevitable routine has unsurprisingly returned. So please join us as we hoist a cup of stimulation to a year of fresh challenges that await. Meanwhile, here are some tidbits to help you ease in. Hope your day goes well and you find it manageable.

Newly unearthed documents show the Food and Drug Administration failed to use its policing powers to make sure a program to curb improper prescribing of opioids was effective, The New York Times writes, citing research in JAMA. In 2011, the FDA asked the makers of OxyContin and other addictive long-acting opioids to pay for safety training for more than half the physicians prescribing the drugs, and to track the effectiveness of the training and other measures in reducing addiction, overdoses, and deaths. But the FDA was never able to determine whether the program worked

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Concerning the final SUN Pharma article re the Halol 483, the (financial?) analysts who are concluding that these issues are ‘not so serious’ must not have read the 483 in question – or they are making a ‘buy on the dip’ recommendation. This is a case where a review of the ‘raw data’ is in order: [pdf – 3 Mb]

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy